News 
Market Data 
Discover
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$LVGI Limitless Venture Group Inc. (OTCBB: LVGI)
$WPWR Well Power, Inc. (WPWR) – Promoting Clean Energy Solutions WPWR
Well Power is seeking to engage the attention of oil and gas producing companies in its operations. To accomplish this, the company is employing a two-pronged approach: (1) it is aiming to educate them about the unique micro-refinery unit it is backing; and (2) it is working on creating partnership opportunities that make these companies allies.
Well Power already has a strong ally in ME Resources (“MEC”), the license holder developing an economical, mobile and scalable Micro-Refinery Unit (the “MRU”) to process raw natural gas into clean power and green fuel (diluents, drop-in diesel and pipeline quality synthetic crude). MEC’s proposed solution works in chorus; it concurrently reduces carbon dioxide (CO2) emissions while creating positive income streams from minimal capital spending.
The MRU has modular configuration flexibilities. The unit is scalable, mobile, cost-effective, energy efficient, high yield, single vessel, skid mounted, custom configured and being primed to turn wasted gas into clean power and engineered fuels (i.e. revenue). According to MEC’s designs, the MRU assembles proven industrial technologies with a proprietary micro-reactor system for hydrocarbon processing and catalytic reactions. A notably novel system, this process is also the key technology component that enables the unit to be easily transported and financially viable.
Designed to process raw natural gas flows of between 75 Mcf to 250 Mcf, the MRU first conditions then converts methane and condensates to Syngas (carbon monoxide and hydrogen). Following this step, a Fischer-Tropsch reaction occurs that produces power from the heat generated by exothermic reactions and combustion as well as green fuel.
In short, once the micro-refinery unit is developed, its advantages would be ample:
• Energy efficient
• High yield (C5+ > 50%)
• Improved safety
• Units > 100 MCFD
• Mobility advantages
$WPWR Well Power, Inc. (WPWR) – Promoting Clean Energy Solutions WPWR
Well Power is seeking to engage the attention of oil and gas producing companies in its operations. To accomplish this, the company is employing a two-pronged approach: (1) it is aiming to educate them about the unique micro-refinery unit it is backing; and (2) it is working on creating partnership opportunities that make these companies allies.
Well Power already has a strong ally in ME Resources (“MEC”), the license holder developing an economical, mobile and scalable Micro-Refinery Unit (the “MRU”) to process raw natural gas into clean power and green fuel (diluents, drop-in diesel and pipeline quality synthetic crude). MEC’s proposed solution works in chorus; it concurrently reduces carbon dioxide (CO2) emissions while creating positive income streams from minimal capital spending.
The MRU has modular configuration flexibilities. The unit is scalable, mobile, cost-effective, energy efficient, high yield, single vessel, skid mounted, custom configured and being primed to turn wasted gas into clean power and engineered fuels (i.e. revenue). According to MEC’s designs, the MRU assembles proven industrial technologies with a proprietary micro-reactor system for hydrocarbon processing and catalytic reactions. A notably novel system, this process is also the key technology component that enables the unit to be easily transported and financially viable.
Designed to process raw natural gas flows of between 75 Mcf to 250 Mcf, the MRU first conditions then converts methane and condensates to Syngas (carbon monoxide and hydrogen). Following this step, a Fischer-Tropsch reaction occurs that produces power from the heat generated by exothermic reactions and combustion as well as green fuel.
In short, once the micro-refinery unit is developed, its advantages would be ample:
• Energy efficient
• High yield (C5+ > 50%)
• Improved safety
• Units > 100 MCFD
• Mobility advantages
$PMCB Pharmacyte Biotech Inc (OTCMKTS:PMCB) Soars, Opens Floodgates For Catalysts
https://www.insiderfinancial.com/pharmacyte-biotech-inc-otcmktspmcb-soars-opens-floodgates-for-catalysts/118471/
$PMCB Technical Buzz on PharmaCyte Biotech, Inc. (OTCPK:PMCB)
http://wslnews.com/technical-buzz-on-pharmacyte-biotech-inc-otcpkpmcb/31920/
$PMCB Colon Cancer Pipeline Market 2016 Review Report Covering Therapeutics Development
http://www.prnewswire.com/news-releases/colon-cancer-pipeline-market-2016-review-report-covering-therapeutics-development-587207931.html
$PMCB PharmaCyte Executives Meet With Translational Drug Development to Advance Pancreatic Cancer Clinical Trial
January 25, 2016
SILVER SPRING, Md., Jan. 25, 2016 (GLOBE NEWSWIRE) -- PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that its Chief Executive Officer, Kenneth L. Waggoner, and its Chief Operating Officer, Dr. Gerald W. Crabtree, recently met with principals of Translational Drug Development (TD2) at TD2’s facilities in Scottsdale, Arizona. The meeting was held to discuss a number of aspects related to PharmaCyte’s upcoming clinical trial in pancreatic cancer and the structure of the Investigational New Drug Application (IND) that must be submitted to the FDA and found acceptable before the clinical trial can begin. PharmaCyte has contracted with TD2 to be the lead Contract Research Organization (CRO) to prepare for and conduct PharmaCyte’s clinical trial in pancreatic cancer.
In its clinical trial, PharmaCyte’s pancreatic cancer treatment (microcapsules containing live cells that convert the cancer prodrug ifosfamide into its cancer-killing form together with low doses of ifosfamide) will be compared with the combination of the cancer drug capecitabine plus radiation therapy. The clinical trial will be an open-label, “two-armed,” randomized multi-site trial.
The morning session addressed how the clinical trial will be structured and conducted. It was determined that there will be several cancer centers in the United States, with a number of study sites in Europe and possibly Australia. Discussions also dealt with suggested changes related to the number of patients in each arm of the trial, inclusion/exclusion criteria for patients that will be enrolled in the trial and possible sites at which the trial will be conducted.
The afternoon session focused on the IND and the timeline for filing it with the FDA. The afternoon session also included discussions related to the content and preparation of the Chemistry, Manufacturing and Controls (CMC) section of the IND. The CMC section is a pivotal part of the IND and will be a major focus of the FDA when it examines PharmaCyte’s IND submission. TD2 and Chamow & Associates (Chamow) will both prepare the CMC section of the application. Chamow has already performed an inspection and audit of Austrianova’s live-cell encapsulation facility in Bangkok, Thailand. That is the facility where the genetically modified live cells will be encapsulated using the Cell-in-a-Box® technology that are part of PharmaCyte’s pancreatic cancer treatment.
In commenting on the sessions at TD2, Waggoner stated, “These face-to-face meetings with TD2’s clinical trial team were extremely important and exceedingly helpful to PharmaCyte in finalizing the design of the clinical trial. We believe they will prove to be invaluable as we move forward with the preparations for our upcoming clinical trial in pancreatic cancer. The interactions that we had with the team at TD2 in this one day alone reinforce our belief that, in TD2, we have the finest CRO available in which to put our trust that PharmaCyte’s clinical trial will be prepared and conducted as well as it could be.”
About PharmaCyte Biotech
PharmaCyte Biotech is a clinical stage biotechnology company focused on developing and preparing to commercialize treatments for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as “Cell-in-a-Box®.” This unique and patented technology will be used as a platform upon which treatments for several types of cancer and diabetes are being developed.
PharmaCyte’s treatment for cancer involves encapsulating genetically modified live cells that convert an inactive chemotherapy drug (ifosfamide) into its active or “cancer-killing” form. These encapsulated live cells are placed as close to a cancerous tumor as possible. Once implanted in a patient, ifosfamide is then given intravenously at one-third the normal dose. The ifosfamide is carried by the circulatory system to where the encapsulated cells have been placed. When ifosfamide, which is normally activated in the liver, comes in contact with the encapsulated live cells, activation of the drug takes place at the source of the cancer without any side effects from the chemotherapy. This “targeted chemotherapy” has proven remarkably effective and safe to use in past clinical trials.
In addition to developing a novel treatment for cancer, PharmaCyte is developing a treatment for Type 1 diabetes and Type 2 insulin-dependent diabetes. PharmaCyte plans to encapsulate a human cell line that has been genetically engineered to produce, store and release insulin in response to the levels of blood sugar in the human body. The encapsulation will be done using the Cell-in-a-Box® technology.
Safe Harbor
This press release may contain forward-looking statements regarding PharmaCyte Biotech and its future events and results that involve inherent risks and uncertainties. The words "anticipate," "believe," "estimate," "expect," "intend," "plan" and similar expressions, as they relate to PharmaCyte or its management, are intended to identify forward-looking statements. Important factors, many of which are beyond the control of PharmaCyte, could cause actual results to differ materially from those set forth in the forward-looking statements. They include PharmaCyte's ability to continue as a going concern, delays or unsuccessful results in preclinical and clinical trials, flaws or defects regarding its product candidates, changes in relevant legislation or regulatory requirements, uncertainty of protection of PharmaCyte’s intellectual property and PharmaCyte’s continued ability to raise capital. PharmaCyte does not assume any obligation to update any of these forward-looking statements.
More information about PharmaCyte can be found at www.PharmaCyte.com. It can also be obtained by contacting Investor Relations.
Investor Relations:
PharmaCyte Biotech, Inc.
Investor Relations Department
Telephone: 917.595.2856
$PMCB Johnson & Johnson and Big Pharma Could Find a Diabetes "Cure" With PharmaCyte Biotech's Type 1 Diabetes Treatment
Johnson & Johnson (J&J), like much of the biopharmaceutical industry worldwide, is aware of the desperate necessity for a Type 1 diabetes treatment. In fact, Diego Miralles, J&J's head of global innovation, said that his company's recent decision to partner with a privately held San Diego biotech was to "hedge our bets to make sure we would win in this space." Johnson & Johnson's deal with ViaCyte, Inc. is an effort to speed up the development of ViaCyte's stem cell treatment for Type 1 diabetes. Winning in the diabetes space, however, might mean that Johnson & Johnson or another larger company in the biopharmaceutical industry will need to take a long look at PharmaCyte Biotech (OTCQB: PMCB), a small Silver Spring, Maryland firm with its own Type 1 diabetes treatment.
After sitting in on PharmaCyte's second annual International Diabetes Consortium meeting in Vienna, Austria, it was clear that PharmaCyte has a treatment that many other companies, organizations and research institutes have yet to prove they're capable of producing. It is this treatment that Johnson & Johnson and other biopharmaceutical companies should be eyeing very closely. In order to pull off the feat of developing a successful treatment or "cure" for those who are insulin dependent, most researchers are looking for three key ingredients. And PharmaCyte has all three: (1) a cell line capable of producing insulin that can act as an "artificial pancreas," (2) an encapsulation technology that can house the cell line inside the body and keep it protected from the body's immune system, and finally (3) a team of experts in the diabetes arena that can bring the treatment to life.
PharmaCyte's treatment for type 1 diabetes and type 2 insulin-dependent diabetes is an encapsulated human cell line, called the Melligen cell line, which are liver cells that have been genetically modified to produce, store and release insulin in response to blood glucose levels in their surroundings. PharmaCyte will encapsulate the Melligen cells using its signature live-cell encapsulation technology, Cell-in-a-Box®.
Developing a successful diabetes treatment for Type 1 diabetics all starts with a cell line that is capable of producing insulin on demand. Unlike most who have turned to islet cells or stem cells, PharmaCyte has instead turned to Professor Ann Simpson, one of the 17 members on PharmaCyte's international diabetes consortium, and her colleagues at the University of Technology-Sydney in Australia. Professor Simpson and her team conducted numerous tests during the various stages of the development process and studies were carried out to show that Melligen cells secreted insulin in response to physiological concentrations of glucose (blood sugar). Furthermore, when Melligen cells were transplanted into diabetic mice whose immune systems were essentially not functioning, the blood glucose levels of the mice became normal. This observation illustrates that Melligen cells can reverse the diabetic condition.
Their work was published in a major research article titled "Reversal of diabetes following transplantation of an insulin-secreting human liver cell line: Melligen cells" in the journal Molecular Therapy - Methods & Clinical Development: http://www.nature.com/articles/mtm201511
The authors of the article note that, for the Melligen cells to be effective in treating Type 1 diabetes in humans where the insulin-producing beta cells of the pancreas have been destroyed, it will be necessary to protect these cells from rejection by the body's immune system after they have been introduced into the body. The article points out that one way to protect the Melligen cells would be to encapsulate the cells in protective "cocoons" prior to being placed into a diabetic patient. If this is done, the authors believe that encapsulated Melligen cells may offer a cure for Type 1 diabetes.
Enter step 2 of PharmaCyte Biotech's three-pronged approach, an encapsulation technology capable of protecting the genetically engineered live cells inside. The ability to encapsulate a cell line and keep it protected from immune system attack to treat diabetes has been called the "holy grail" of cell encapsulation. PharmaCyte's live-cell encapsulation technology, Cell-in-a-Box®, appears to be the ideal encapsulation technology for this purpose. In fact, Melligen cells have already been successfully encapsulated using the Cell-in-a-Box® process, and the first preclinical studies have shown that Melligen cells are equally as safe inside the Cell-in-a-Box® capsules as the encapsulated cells that PharmaCyte will be using in its upcoming FDA human clinical trials in advanced pancreatic cancer.
So, with the Melligen cell line in place, and with Cell-in-a-Box® set to house the cell line to keep it protected, the final piece to developing a successful treatment for Type 1 diabetes is a team of experts who can put it all together, test it, modify the treatment where necessary, perfect the dosing in a number of animal models and get the treatment into clinical trials as quickly as possible.
PharmaCyte's CEO, Kenneth L. Waggoner, has assembled 17 experts in the field of diabetes from all over the globe. This group makes up PharmaCyte's International Diabetes Consortium. They have all come together to work toward one goal -- developing an "artificial pancreas" or a "cure" for insulin dependent diabetes. All of these experts are working at the same time in their specific area of expertise rather than waiting for each experiment to run its course before moving on to the next group of experts. It is this approach that should expedite PharmaCyte's path to human clinical trials. PharmaCyte's approach should provide answers more quickly for those larger biopharmaceuticals that expect to win the race to the first truly long-term successful type 1 diabetes treatment.
About Stock Market Media Group
Stock Market Media Group is a Content Development IR firm offering a platform for corporate stories to unfold in the media with research reports, corporate videos, CEO interviews and feature news articles. This article was written based upon publicly available information. PharmaCyte Biotech has not endorsed this article, and Stock Market Media Group was not compensated for its production.
Stock Market Media Group may from time to time include our own opinions about the companies, their business, markets and opportunities in our articles. Any opinions we may offer about any of the companies we write about are solely our own, and are made in reliance upon our rights under the First Amendment to the U.S. Constitution, and are provided solely for the general opinionated discussion of our readers. Our opinions should not be considered to be complete, precise, accurate, or current investment advice, or construed or interpreted as research. Any investment decisions you may make concerning any of the securities we write about are solely your responsibility based on your own due diligence. Our publications are provided only as an informational aid, and as a starting point for doing additional independent research. We encourage you to invest carefully and read the investor information available at the web site of the U.S. Securities and Exchange Commission at: www.sec.gov, where you can also find all of PMCB's filings and disclosures. We also recommend, as a general rule, that before investing in any securities you consult with a professional financial planner or advisor, and you should conduct a complete and independent investigation before investing in any security after prudent consideration of all pertinent risks.
We are not a registered broker, dealer, analyst, or adviser. We hold no investment licenses and may not sell, offer to sell or offer to buy any security. Our publications about any of the companies we write about are not a recommendation to buy or sell a security.
For more information: www.stockmarketmediagroup.com.
|
Followers
|
48
|
Posters
|
|
|
Posts (Today)
|
0
|
Posts (Total)
|
933
|
|
Created
|
12/31/15
|
Type
|
Premium
|
| Moderators | |||
